Epoetin zeta (Retacrit®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000389
English
Authors' recommendations:
Epoetin zeta (Retacrit®) is not recommended for use within NHS Wales for the treatment of anaemia associated with chronic kidney disease, reduction of transfusion requirements in adult patients receiving chemotherapy or to increase the yield of autologous blood from patients in a predonation programme. The case for cost effectiveness of epoetin zeta (Retacrit®) has not been proven.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=158220&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Erythropoietin
- Anemia
- Kidney Failure, Chronic
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.